Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neurotoxicity Syndromes 1Hematologic Neoplasms 1Delirium 1

Interventions

fludarabine 6trametinib 5Specimen Handling 5Standard of Care 4Practice Guidelines as Topic 4Magnetic Resonance Spectroscopy 4fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Melphalan 3Interviews as Topic 3GSK2636771 3Cyclophosphamide 3Crizotinib 3Busulfan 3Biopsy 3Antilymphocyte Serum 3AP 1903 reagent 3venetoclax 2thymoglobulin 2palbociclib 2osimertinib 2letermovir 2dabrafenib 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Neoplasms × haloperidol decanoate × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡